MOUNTAIN VIEW, Calif., Oct. 20 /PRNewswire-FirstCall/ -- VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that Dr. Kishore Gadde will give an oral presentation on positive results from a Phase 2 clinical trial of Qnexa(TM)(previously known as VI-0521), an investigational oral treatment for obesity, at the North American Association for the Study of Obesity (NAASO) 2006 Annual Scientific Meeting. The NAASO Meeting will be held in Boston at the Hynes Convention Center from Friday, October 20th through Tuesday, October 24th.
In addition to the top-line data previously disclosed for this trial, Dr. Gadde will present additional data on weight-loss and the observed benefit of Qnexa(TM) with respect to multiple factors contributing to metabolic syndrome.
The presentation will be delivered during the oral abstract session entitled: Clinical Studies: Pharmacotherapy. Details of this session and the presentation are as follows:
Date: Sunday, October 22, 2006 Time: 11:00 a.m. - 12:45 p.m. Room: Ballroom B Description: During this session, speakers will present findings from recent research studies that have implications in the diagnosis, treatment, and prevention of obesity. Abstract: A 24-week Randomized Controlled Trial of VI-0521, a Combination Weight Loss Therapy, in Obese Adults - Abstract No. 55-OR. About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. VIVUS has three products that are positioned to enter Phase 3 clinical trials, and one product currently under NDA review by the FDA. The investigational pipeline includes: Qnexa(TM), for which a Phase 2 study has been completed for the treatment of obesity; Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), for which a Phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms; avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED); and, MUSE(R), which is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company’s web site at www.vivus.com .
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on VIVUS’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that the EvaMist NDA submission will be filed with the FDA for substantive review, or that it will be approved in a timely basis, or at all. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ended December 31, 2005 and periodic reports filed with the Securities and Exchange Commission.
CONTACT: VIVUS, Inc. Vida Communication Timothy E. Morris Stephanie Diaz & Tim Brons Chief Financial Officer 415-675-7400 650-934-5200
VIVUS, Inc.
CONTACT: Timothy E. Morris, Chief Financial Officer of VIVUS, Inc.,+1-650-934-5200; or Stephanie Diaz, or Tim Brons, Vida Communication,+1-415-675-7400
Web site: http://www.vivus.com/
